Meeting
2024 ASCO Genitourinary Cancers Symposium
Preliminary data from a dose-escalation phase 1 study with HP518, an AR PROTAC degrader: Safety, tolerability, pharmacokinetics (PK), and first assessment of anti-tumor activity in patients (Pts) with metastatic castration-resistant prostate cancer (mCRPC).
Authors
Arun Azad
Peter MacCallum Cancer Centre; and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia
Arun Azad , Howard Gurney , Craig Underhill , Lisa Horvath , Mark Voskoboynik , Xinghai Li , Ivan King , Lisa Shao , Yiyun Dai , Frank Perabo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT05252364
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 124)
DOI
10.1200/JCO.2024.42.4_suppl.124
Abstract #
124
Poster Bd #
E17
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 1/2 trial of oral EPI-7386 (masofaniten) in combination with enzalutamide (Enz) compared to Enz alone in patients with metastatic castration-resistant prostate cancer (mCRPC): Phase 1 (P1) results and phase 2 (P2) design.
First Author: Christos Kyriakopoulos
Poster
2023 ASCO Annual Meeting
A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors.
First Author: Fei Ma
Poster
2023 ASCO Annual Meeting
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of Bcl-2 inhibitor BGB-11417 in adult patients with mature B-cell malignancies.
First Author: Caixia Li
Poster
2023 ASCO Annual Meeting
Phase I trial of enzalutamide (Enz) plus the glucocorticoid receptor antagonist relacorilant (Rela) for patients with metastatic castration resistant prostate cancer.
First Author: Kunal Desai